Title Physician

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43)

NCT ID : 03740165
Protocol Number : MK-7339-001
Phase : 3
Location : Burbank, CA
Dr. Mena

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas

NCT ID : 02033616
Protocol Number : CL-OVA-P01-00-US
Phase : 2
Location : Burbank, CA
Dr. Mena

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

NCT ID : 04291105
Phase : 2
Location : Santa Monica, CA
Dr. O'Day

Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

NCT ID : 04406623
Phase : 1
Location : Santa Monica, CA
Dr. O'Day

⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

NCT ID : 03802123
Phase : 2
Location : Santa Monica, CA
Dr. O'Day

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT ID : 03170960
Phase : 1 and 2
Location : Santa Monica, CA
Dr. Twardowski

Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy

NCT ID : 02033616
Phase : 2
Location : Burbank, CA
Dr. Friedman

A Phase I Study of AGEN1181, an Fe-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

NCT ID : 03860272
Protocol Number : C-800-01
Phase : 1
Location : Santa Monica, CA
Dr. O'Day

Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

NCT ID : 03684785
Protocol Number : AST-008-102
Phase : 1b/2
Location : Santa Monica, CA
Dr. O'Day

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT ID : 03633110
Protocol Number : GEN-009-101
Phase : 1 and 2
Location : Santa Monica, CA
Dr. Twardowski